PFI-2 HCl is a potent and selective inhibitor of the protein lysine methyltransferase SETD7 (also known as SET7/9). It is widely used in epigenetic research to probe the biological roles of SETD7-mediated methylation events. By inhibiting SETD7, PFI-2 HCl helps researchers study the impact of this enzyme on various cellular processes, including gene expression, cell cycle regulation, and signal transduction pathways. One key application is in cancer research, where SETD7 has been implicated in the regulation of tumor suppressor proteins and oncogenic transcription factors. PFI-2 HCl enables targeted suppression of SETD7 activity, allowing scientists to assess its influence on cancer cell proliferation, differentiation, and apoptosis. Additionally, PFI-2 HCl is used to investigate the role of SETD7 in inflammatory responses and metabolic diseases. Its high selectivity reduces off-target effects, making it a valuable tool for validating SETD7 as a therapeutic target in drug discovery. The compound is primarily utilized in in vitro assays and cellular models, supporting the development of novel epigenetic therapies.